Individual-level data on the relationships of progression-free survival, post-progression survival, and tumor response with overall survival in patients with advanced non-squamous non-small cell lung cancer.

摘要: The effects of first-line chemotherapy on overall survival (OS) might be confounded by subsequent therapies in patients with non-small cell lung cancer (NSCLC). We examined whether progression-free (PFS), post-progression (PPS), or tumor response could valid surrogate endpoints for OS after chemotherapies advanced NSCLC using individual-level data, given the lack research this area. Between April 2009 and June 2011, 50 non-squamous treated cisplatin pemetrexed as were analyzed. relationships PFS, PPS, analyzed at individual level. Spearman rank correlation analysis linear regression showed that PPS was strongly correlated (r = 0.89, P < 0.05, R2 0.79), PFS moderately 0.67, 0.39), shrinkage weakly 0.36, 0.14). Performance status beginning second-line treatment, best to number regimens used progression following significantly associated (P 0.05). Analysis data suggested a unknown oncogenic driver mutations therefore limited options chemotherapy. Our findings also suggest treatment disease may greatly influence OS. These results should validated other larger populations.